ACRS
Aclaris Therapeutics, Inc.
There isn't enough reported data to score ACRS yet.
ACRS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
ACRS's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
ACRS PE Valuation
ACRS has no meaningful PE right now: it lost money over the past year.
ACRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ACRS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
ACRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.58 | +$1.00 |
| Q2 2026 | -$0.58 | +$0.99 |
| Q1 2026 | -$0.56 | +$1.03 |
| Q4 2025 | -$0.53 | +$1.18 |
| Q3 2025 | -$1.58 | -$1.06 |
| Q2 2025 | -$1.57 | -$0.75 |
| Q1 2025 | -$1.59 | -$0.50 |
| Q4 2024 | -$1.71 | -$0.44 |
ACRS is still losing money, but far less than before: $0.58 per share over the past year, against $3.90 at its worst in late 2019.
ACRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5M | -55% |
| Q2 2026 | $1.6M | -8.3% |
| Q1 2026 | $2M | +37% |
| Q4 2025 | $1.3M | -86% |
| Q3 2025 | $3.3M | -24% |
| Q2 2025 | $1.8M | -36% |
| Q1 2025 | $1.5M | -39% |
| Q4 2024 | $9.2M | -48% |
ACRS's revenue has slid since its 2022 peak: $1M last quarter, down 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1441% | -921 points |
| Q2 2026 | -1488% | -452 points |
| Q1 2026 | -1112% | +131 points |
| Q4 2025 | -1756% | -673 points |
| Q3 2025 | -520% | -279 points |
| Q2 2025 | -1036% | -571 points |
| Q1 2025 | -1243% | -453 points |
| Q4 2024 | -1082% | -1059 points |
ACRS's operating margin was −1441% last quarter, down 921 points from the same quarter a year ago.
ACRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24.1M | -$13.1M |
| Q2 2026 | -$19.9M | -$9.9M |
| Q1 2026 | -$18.2M | -$5.1M |
| Q4 2025 | -$13.2M | -$4.2M |
| Q3 2025 | -$11M | -150% |
| Q2 2025 | -$10M | +$2.3M |
| Q1 2025 | -$13.1M | +$7.9M |
| Q4 2024 | -$8.9M | -$1.7M |
ACRS has burned cash in almost every quarter: −$75M over the past year, against −$43M the year before.
ACRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +6.7M shares |
| 1 year | +22% | +26.8M shares |
| 3 years | +112% | +78.8M shares |
| 5 years | +177% | +95.5M shares |
| Available history | +262% | +108M shares |
ACRS has 149M diluted shares, up 22% from a year ago.
ACRS Net Leverage
ACRS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ACRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 22.7 | Neutral |
ACRS's weekly RSI is 44 (neutral) and its Stochastic is 23 (neutral).
ACRS PE vs Healthcare Sector
ACRS has no meaningful PE right now: it lost money over the past year.
ACRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.03 | 0.7% below |
| 20 week MA | $5.03 | 20% below |
| 50 week MA | $4.27 | 6.3% below |
| 100 week MA | $3.09 | 29% above |
| 200 week MA | $3.91 | 2.3% above |
ACRS has slipped below its 8-, 20- and 50-week averages, though it's still 2.3% above its 200-week average.
ACRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.92 | $7.61 | +296% |
| 2021 | $7.61 | $15.4 | +103% |
| 2022 | $15.4 | $15.1 | -2.3% |
| 2023 | $15.1 | $1.05 | -93% |
| 2024 | $1.05 | $2.73 | +160% |
| 2025 | $2.73 | $3.03 | +11% |
| 2026 YTD | $3.03 | $4.00 | +32% |
ACRS's yearly returns have swung widely, from +296% in 2020 to −93% in 2023. It's up 32% so far in 2026.